"Contrary to other tumor types, GBM has not seen much success in targeting by immunotherapeutic agents due to a low tumor mutation burden, high tumor heterogeneity and presence of the blood brain barrier, among other factors. Hence, Dr. Arumugaswami's characterization of the neoantigen landscape and immune responses to Lm - constructs may lead to the development of novel therapies with clinical activity in this elusive cancer." About Advaxis, Inc. Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm -based antigen delivery products.